Industrial pharmacists working within the pharmaceutical industry make an important contribution to the infection control agenda through their involvement in developing new medicines, including antimicrobial agents. This paper reviews the main activities of industrial pharmacists in the pharmaceutical industry and the developmental history of some notable antimicrobial drugs.
Anon (2009) Not enough being done to develop new antibiotics despite increasing burden of resistance. The Pharmaceutical Journal283: 320.
2.
Association of the British Pharmaceutical Industry ( 2007) A-Z of medicines research. ABPI.
3.
Association of the British Pharmaceutical Industry ( 2008) Code of Practice for the Pharmaceutical Industry . ABPI.
4.
Association of the British Pharmaceutical Industry ( 2010) Online: http://www.abpi.org.uk/ (accessed 28 February 2010).
5.
Brown ME, Khan S. ( 2007) How does one become a qualified person?Tomorrow’s Pharmacist28-29.
6.
Brumfitt W., Hamilton-Miller JM ( 1988) The changing face of chemotherapy. Postgraduate Medical Journal64: 552-8.
7.
Bryan J. ( 2005) Microdoses open new horizons for trials. The Pharmaceutical Journal275: 54.
8.
Bryan J.(2009) Superseding antifungal creams and pessaries - the story of fluconazole . The Pharmaceutical Journal283: 73-4.
9.
Cartwright AC ( 2008) Industrial pharmacists are an endangered species . The Pharmaceutical Journal280: 49.
10.
Chamberlain J. ( 2008a) Advances in laboratory efficiency. The Pharmaceutical Journal281: 517.
11.
Chamberlain J. ( 2008b) Methods to analyse counterfeit medicines. The Pharmaceutical Journal280: 759.
12.
Chamberlain J.(2009) The current state of dissolution testing. The Pharmaceutical Journal282: 52.
13.
Connelly D. ( 2008) Nanomedicines are now considered mainstream. The Pharmaceutical Journal281: 176.
14.
Connolly S. ( 2008) My route into industrial pharmacy. The Pharmaceutical Journal281:250.
15.
Demain AL, Elander RP ( 1999) The β-lactam antibiotics: past, present, and future . Antonie van Leeuwenhoek75: 5-19
16.
Edwards IR, Aronson JK ( 2000) Adverse drug reactions: definitions, diagnosis, and management . Lancet356: 1255-9.
17.
Florey HW ( 1945) The use of micro-organisms for therapeutic purposes . British Medical Journal635-42.
18.
Goundrey-Smith S. ( 2007) Duel or duet? The relationship between pharmacists and the drug industry. The Pharmaceutical Journal278: 454.
19.
Goundrey-Smith S. ( 2008) Why we need industrial pharmacists. The Pharmaceutical Journal280: 304.
20.
Greenwood D. ( 1992) The quinine connection. Journal of Antimicrobial Chemotherapy30: 417-27.
21.
Hauben M., Bate A.(2009) Decision support methods for the detection of adverse events in post-marketing data. Drug Discovery Today14(7/8): 343-57.
22.
Hirsch MS, Kaplan JC ( 1987) Treatment of human immunodeficiency virus infections . Antimicrobial Agents and Chemotherapy31(6): 839-43.
23.
Kirby-Smith J. ( 2009) Interesting work in regulatory affairs. The Pharmaceutical Journal282: 658.
24.
Martin M.(2009) My route into medical writing. The Pharmaceutical Journal282: 500.
25.
Medicines and Healthcare products Regulatory Agency ( 2008) Medicines and Medical Devices Regulation: What you need to know. London: The Medicines and Healthcare products Regulatory Agency.
26.
Moberly T. ( 2008) Why clinical trials need pharmacists. The Pharmaceutical Journal280: 210.
27.
Patel S., Smith M. ( 2005) A day in the life of an industrial pharmacist: two perspectives . Tomorrow’s Pharmacist41-2.
28.
Pharmaceutical Information and Pharmacovigilance Association (2010) Online: http://www.pipaonline.org (accessed 28 February 2010).
29.
Richards C.(2009) TOPRA 2009: Unequal access to medicines information prompts EC action . The Pharmaceutical Journal282: 356.
30.
Stevens DL, Dotter B., Madras-Kelly K. ( 2004) A review of linezolid: the first oxazolidinone antibiotic . Expert Reviews of Anti-Infective Therapy2(1): 51-9.
31.
Stone EA, Fung HB, Kirschenbaum HL ( 2002) Caspofungin: an echinocandin antifungal agent. Clinical Therapeutics24(3): 351-77.
32.
Sucher AJ, Chahine EB, Balcer HE(2009) Echinocandins: the newest class of antifungals. Annals of Pharmacotherapy43(10): 1647-57.
33.
Talbot JCC, Nilsson BS ( 1998) Pharmacovigilance in the pharmaceutical industry . British Journal of Clinical Pharmacology45(5): 427-31.
34.
The Organisation for Professionals in Regulatory Affairs ( 2009) "What is Regulatory Affairs" press release. Online: http://www.topra.org/careers/what-regulatory-affairs (accessed 28 February 2010).
35.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2006) Guidance for industry, investigators, and reviewers. Exploratory IND studies . Food and Drug Administration
36.
Wicks SR ( 2000) Careers and development in a growing industrial sector .The Pharmaceutical Journal264: 150-1.
37.
Wood IV ( 2008) Medical affairs an attractive option for pharmacists . The Pharmaceutical Journal280: 120.
38.
Wynne-Howells C. ( 2006) Nanotechnology: current and potential applications in drug delivery systems. The Pharmaceutical Journal277: F31.
